The Route 66 Endometrial Cancer SPORE invites applications (including renewal and resubmitted applications) for the 2025-2026 cycle of Career Enhancement Program (CEP) and Developmental Research Program (DRP) awards. Investigators from Washington University, University of New Mexico, and University of Oklahoma are eligible to apply.
Flyer is attached and full details may be found here:
https://obgyn.wustl.edu/research/spore-in-endometrial-cancer/cep-drp/call-for-proposals-in-endometrial-cancer-research/The goal of the Career Enhancement Program (CEP) is to recruit and support early career and established investigators in translational endometrial cancer research. The CEP builds upon existing productive collaborations between outstanding researchers with expertise in translational endometrial cancer at Washington University, University of New Mexico, and University of Oklahoma. We will further enhance these collaborations by providing funding support, didactic training, career development and mentoring to new investigators in the field.
The goals of the Route 66 Endometrial Cancer SPORE Developmental Research Program (DRP) are to support innovative, early-stage research in endometrial cancer, to develop pilot projects to the point of inclusion as full SPORE projects, to increase the number of investigators committed to endometrial cancer, and to diversify the workforce.
Award amounts are up to $50,000 for one year, with budget requests up to $75,000 considered with a unique scope of work and strong justification. Awards may be renewed for a second year contingent on adequate progress, availability of funds, and strategic priorities.
These applications will need to be routed in SoonerTrack and reviewed by ORA before submission.
College of Medicine Alumni Association (COMAA) - COMAA awards are important resources for funding basic and clinical research projects of new and early-stage investigators in the College of Medicine. The guidelines are included with this notice attached. Deadline is Wednesday, March 26, 2025 at 5:00PM.
Presbyterian Health Foundation (PHF) Bridge Grant Program – Request for Applications
The primary objective of the PHF Bridge Grant Program is to provide funding to enhance OUHSC faculty competitiveness for extramural funding. OUHSC Principal Investigators are eligible if they meet the following criteria: 1) have submitted an extramural application within the past 18 months that was scored but not funded, 2) are requesting over $750,000 in total direct costs and over $200,000 in total facilities and administration (F&A) costs; and 3) received a review that ranks applications and provides critiques. This program provides funding for up to
$75,000 for one year. Guidelines and Application Form are attached or can be found at
https://research.ouhsc.edu/research-administration/grants/funding-opportunities/phf-funding. If you have any questions, please email
Kathy-Kyler@ouhsc.edu.
Presbyterian Health Foundation (PHF) Clinician Scientist Development Grant Program Year 1 – Request for Applications
The primary objective of the PHF Clinician Scientist Development Grant Program is to provide funding to a new or early-stage clinician scientist faculty member. This award is designed to support the applicant’s clinical and/or translational research project and to assist him or her with advancing this research project to a level that will be competitive for funding through a federal career development award mechanism. This program can provide funding for up to two years. The second year of funding will be based on successful achievement of identified milestones, completion of an application for Year Two funds, and whether funds are available.
The Principal Investigator must be an OUHSC primary faculty member with appointment at OUHSC as an Assistant Professor. Fellows are permitted to apply with a letter from their department chair guaranteeing the fellow will hold a faculty position that is not dependent on receipt of the grant at the award start date. New or early-stage clinical scientist faculty members with Temporary Faculty appointments (faculty with academic titles such as instructor, lecturer, or titles modified by prefixes such as visiting, adjunct, clinical, or temporary research appointments with suffix “of Research”) must obtain approval from the Vice President for Research before submitting an application for this program. Approval will require a letter from their Department Chairperson indicating a departmental commitment of salary, research space, and time for development of an independent career at OUHSC. Requests should be sent to
ORA4PHF@ouhsc.edu). Guidelines and Application Form are attached or can be found at
https://research.ouhsc.edu/research-administration/grants/funding-opportunities/phf-funding. If you have any questions, please email
Kathy-Kyler@ouhsc.edu.
Presbyterian Health Foundation (PHF) Technology Advancement Grant (TAG) Program – Request for Applications
Cycles I-III PHF TAG Grant Program Deadline: ROLLING APPLICATIONS
The TAG program replaces the Equipment grant program. The primary objective of the PHF TAG program is to provide partial funding for critically needed research equipment that could be transformative for the research mission at OUHSC. This program is fully aligned with Pillar 1 of the Strategic Plan. The TAG program will proactively and with the help of a committee address campus-wide needs and fill critical gaps, with the goals to grow the research enterprise, expand innovative technology and research infrastructure, and promote addition of new cutting-edge technology on campus. Funding priority will be given to research equipment that will permit OUHSC investigators to be more competitive for external funding and provides support to multiple users. Funds may be used for equipment to be purchased as part of a recruitment package for new faculty or for equipment to support the research of current faculty. If the funds will be used for a new recruit, the recruit must have signed the offer letter with a specific start date or specific start date time frame. Equipment and/or technology funded by PHF is expected to be made available to all researchers at OUHSC, whenever possible. All OUHSC Assistant, Associate, or Full Professors are eligible to apply. Applicants are required to match requested funds. The maximum allowable budget for this program is $500,000 (PHF funding: $250,000; Applicant funding: $250,000). The minimum allowable budget for this program is $60,000 (PHF funding: $30,000; Applicant funding: $30,000). Only one application will be accepted per investigator per year.
New Clinical Study Opportunities
***************************************************************
Please note this is NOT a solicitation for study subjects
***************************************************************
Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:
and safety of Remibrutinib in patients with secondary progressive MULTIPLE
SCLEROSIS
delaying disability progression based on EDSS in patients with nrSPMS (non
relapsing secondary progressive multiple sclerosis)
-
VEXAS clinical study – Novartis
-
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs),
-
MS
-
Sjogren’s Disease
-
Breast Cancer
-
mCRPC (Metastatic Castrate Resistant Prostate Cancer
-
mHSPC (Metastatic Hormone Resistant Prostate Cancer)
-
Pfizer - Request for Proposals (RFP) Integrin beta-6 (IB6) Sigvotatug Vedotin (SV) Translational and Pre-Clinical Research. The intent of this RFP is to support non-interventional Investigator Sponsored Research projects that will advance the understanding of IB6 patterns of expression and clinical outcomes in NSCLC or explore sigvotatug vedotin’s preclinical activity. Due Date: March 20, 2025.
-
Pfizer - New Sickle Cell Disease Fellowship RFP. The goal of this RFP is to support institutions with fellowship programs for hematologists who specialize in treating adults with SCD that also have a strong focus on clinical practice, research, and education to further the understanding of SCD.
Due Date June 12, 2025
Please contact Scott Davis at
scott-davis@ouhsc.edu if you would like to receive more information on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the Office of Research Administration.